U-Blot® IL23A hIgG1 Reference Antibody (Risbio)

Background:IL-23A encodes the p19 subunit of Interleukin-23, a cytokine that plays an important role in the immune response and is secreted by dendritic cells, macrophages and other Antigen-presenting cell. Risankizumab (Skyrizi) is a humanized monoclonal antibody that works by targeting the p19 subunit of Interleukin-23(Il-23) . RISANKIZUMAB specifically binds to the p19 subunit of Il-23 and blocks the interaction between IL-23 and its receptor, thereby inhibiting Th17 cell differentiation and the release of proinflammatory factors such as Il-17 and Il-22. Risankizumab alleviates pathological damage by inhibiting the IL-23/Th17 inflammatory axis, reducing inflammatory cell infiltration and cytokine storm in tissues such as the skin, intestine, and so on.